Neuroendocrine cancer vaccines in clinical trials

References

• Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas39(6), 707–712 (2010).
   PubMed Web of Science ®Google Scholar
• Fujita T, Kobayashi S, Yui R. Paraneuron concept and its current implications. Adv. Biochem. Psychopharmacol.25, 321–325 (1980).
   PubMedGoogle Scholar
• Le Douarin NM. On the origin of pancreatic endocrine cells. Cell53(2), 169–171 (1988).
   PubMed Web of Science ®Google Scholar
• Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr. Relat. Cancer11(1), 1–18 (2004).
   PubMed Web of Science ®Google Scholar
• Yon L, Guillemot J, Montero-Hadjadje M et al. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. J. Clin. Endocrinol. Metab.88(6), 2579–2585 (2003).
   PubMedGoogle Scholar
• Guillemot J, Anouar Y, Montero-Hadjadje M et al. Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma. Int. J. Cancer118(8), 2003–2012 (2006).
   PubMedGoogle Scholar
• Kanehira K, Khoury T. Neuroendocrine markers expression in pancreatic serous cystadenoma. Appl. Immunohistochem. Mol. Morphol.19(2), 141–146 (2011).
   PubMedGoogle Scholar
• Farinola MA, Weir EG, Ali SZ. CD56 expression of neuroendocrine neoplasms on immunophenotyping by flow cytometry: a novel diagnostic approach to fine-needle aspiration biopsy. Cancer99(4), 240–246 (2003).
   PubMedGoogle Scholar
• Bahrami A, Gown AM, Baird GS, Hicks MJ, Folpe AL. Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall. Mod. Pathol.21(7), 795–806 (2008).
   PubMed Web of Science ®Google Scholar
• Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann. Oncol.12(Suppl. 2), S141–S144 (2001).
   Google Scholar
• Slominski A. Neuroendocrine activity of the melanocyte. Exp. Dermatol.18(9), 760–763 (2009).
   PubMed Web of Science ®Google Scholar
• Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol. Rev.80(3), 979–1020 (2000).
   PubMed Web of Science ®Google Scholar
• Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev.84(4), 1155–1228 (2004).
   PubMed Web of Science ®Google Scholar
• Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J.19(2), 176–194 (2005).
   PubMed Web of Science ®Google Scholar
• Eyden B, Pandit D, Banerjee SS. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases. Histopathology47(4), 402–409 (2005).
   PubMedGoogle Scholar
• Navalkele P, O’Dorisio MS, O’Dorisio TM, Zamba GK, Lynch CF. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975–2006. Pediatr. Blood Cancer56(1), 50–57 (2011).
   PubMed Web of Science ®Google Scholar
• Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol.9(1), 61–72 (2008).
   PubMed Web of Science ®Google Scholar
• Dworakowska D, Grossman AB. Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr. Relat. Cancer16(1), 45–58 (2009).
   PubMedGoogle Scholar
• Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract. Res. Clin. Endocrinol. Metab.21(1), 1–14 (2007).
   PubMedGoogle Scholar
• Almeida MQ, Stratakis CA. Solid tumors associated with multiple endocrine neoplasias. Cancer Genet. Cytogenet.203(1), 30–36 (2010).
   PubMedGoogle Scholar
• Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs70(9), 1079–1098 (2010).
   PubMed Web of Science ®Google Scholar
• Wirnsberger G, Hinterberger M, Klein L. Regulatory T-cell differentiation versus clonal deletion of autoreactive thymocytes. Immunol. Cell Biol.89(1), 45–53 (2011).
   PubMed Web of Science ®Google Scholar
• Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci.100(11), 2014–2021 (2009).
   PubMed Web of Science ®Google Scholar
• Coggin JH Jr, Barsoum AL, Rohrer JW, Thurnher M, Zeis M. Contemporary definitions of tumor specific antigens, immunogens and markers as related to the adaptive responses of the cancer-bearing host. Anticancer Res.25(3c), 2345–2355 (2005).
   PubMedGoogle Scholar
• Morran MP, Casu A, Arena VC et al. Humoral autoimmunity against the extracellular domain of the neuroendocrine autoantigen IA-2 heightens the risk of Type 1 diabetes. Endocrinology151(6), 2528–2537 (2010).
   PubMedGoogle Scholar
• Ray S, Chhabra A, Mehrotra S et al. Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clin. Dermatol.27(6), 603–613 (2009).
   PubMed Web of Science ®Google Scholar
• Hofman FM, Stathopoulos A, Kruse CA, Chen TC, Schijns VE. Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells. Anticancer Agents Med. Chem.10(6), 462–470 (2010).
   PubMedGoogle Scholar
• Luo W, Hsu JC, Kieber-Emmons T, Wang X, Ferrone S. Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases. Cancer Chemother. Biol. Response Modif.22, 769–787 (2005).
   PubMedGoogle Scholar
• Liu MA. Immunologic basis of vaccine vectors. Immunity33(4), 504–515 (2010).
   PubMed Web of Science ®Google Scholar
• Shurin MR, Gregory M, Morris JC, Malyguine AM. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow? Expert Opin. Biol. Ther.10(11), 1539–1553 (2010).
   PubMed Web of Science ®Google Scholar
• Maris JM. Recent advances in neuroblastoma. N. Engl. J. Med.362(23), 2202–2211 (2010).
   PubMed Web of Science ®Google Scholar
• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet369(9579), 2106–2120 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Coulie PG, Figdor CG, Adema GJ, De Vries IJ, Hoogerbrugge PM. Targets for active immunotherapy against pediatric solid tumors. Cancer Immunol. Immunother.58(6), 831–841 (2009).
   PubMedGoogle Scholar
• Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest.25(1), 67–77 (2007).
   PubMed Web of Science ®Google Scholar
• Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol.491, 369–402 (2001).
   PubMed Web of Science ®Google Scholar
• Cheung NK, Kushner BH, Cheung IY et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J. Clin. Oncol.16(9), 3053–3060 (1998).
   PubMed Web of Science ®Google Scholar
• Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res.45(6), 2642–2649 (1985).
   PubMed Web of Science ®Google Scholar
• Simon T, Hero B, Faldum A et al. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klin. Padiatr.217(3), 147–152 (2005).
   PubMed Web of Science ®Google Scholar
• Simon T, Hero B, Faldum A et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J. Clin. Oncol.22(17), 3549–3557 (2004).
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med.363(14), 1324–1334 (2010).
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J.16(4), 336–341 (2010).
   PubMed Web of Science ®Google Scholar
• Savai R, Schermuly RT, Pullamsetti SS et al. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. Cancer Res.67(11), 5443–5453 (2007).
   PubMedGoogle Scholar
• Raffaghello L, Prigione I, Airoldi I et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett.228(1–2), 155–161 (2005).
   PubMed Web of Science ®Google Scholar
• Cartellieri M, Bachmann M, Feldmann A et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J. Biomed. Biotechnol.2010, 956304 (2010).
   PubMedGoogle Scholar
• Navid F, Santana VM, Barfield RC. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr. Cancer Drug Targets10(2), 200–209 (2010).
   PubMed Web of Science ®Google Scholar
• Leen AM, Myers GD, Sili U et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med.12(10), 1160–1166 (2006).
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med.14(11), 1264–1270 (2008).
   PubMed Web of Science ®Google Scholar
• Geiger JD, Hutchinson RJ, Hohenkirk LF et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res.61(23), 8513–8519 (2001).
   PubMed Web of Science ®Google Scholar
• Caruso DA, Orme LM, Neale AM et al. Results of a Phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro. Oncol.6(3), 236–246 (2004).
   PubMed Web of Science ®Google Scholar
• Caruso DA, Orme LM, Amor GM et al. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer103(6), 1280–1291 (2005).
   PubMed Web of Science ®Google Scholar
• Russell HV, Strother D, Mei Z et al. A Phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J. Immunother.31(9), 812–819 (2008).
   PubMed Web of Science ®Google Scholar
• Russell HV, Strother D, Mei Z et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J. Immunother.30(2), 227–233 (2007).
   PubMed Web of Science ®Google Scholar
• Bowman LC, Grossmann M, Rill D et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum. Gene Ther.9(9), 1303–1311 (1998).
   PubMed Web of Science ®Google Scholar
• Bowman L, Grossmann M, Rill D et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood92(6), 1941–1949 (1998).
   PubMed Web of Science ®Google Scholar
• Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int. J. Cancer85(5), 659–666 (2000).
   PubMed Web of Science ®Google Scholar
• Ragupathi G, Livingston PO, Hood C et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin. Cancer Res.9(14), 5214–5220 (2003).
   PubMed Web of Science ®Google Scholar
• Chapman PB, Morrissey DM, Panageas KS et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin. Cancer Res.6(3), 874–879 (2000).
   PubMed Web of Science ®Google Scholar
• Ahlman H. Malignant pheochromocytoma: state of the field with future projections. Ann. NY Acad. Sci.1073, 449–464 (2006).
   PubMed Web of Science ®Google Scholar
• Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics26(1), 41–57; discussion 57–48 (2006).
   PubMedGoogle Scholar
• Toh CK, Gao F, Lim WT et al. Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers. Lung Cancer56(2), 161–166 (2007).
   PubMed Web of Science ®Google Scholar
• Zereu M, Vinholes JJ, Zettler CG. p53 and Bcl-2 protein expression and its relationship with prognosis in small-cell lung cancer. Clin. Lung Cancer4(5), 298–302 (2003).
   PubMedGoogle Scholar
• Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin. Biol. Ther.10(6), 983–991 (2010).
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res.12(3 Pt 1), 878–887 (2006).
   PubMed Web of Science ®Google Scholar
• Jones PC, Sze LL, Liu PY, Morton DL, Irie RF. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J. Natl Cancer Inst.66(2), 249–254 (1981).
   PubMed Web of Science ®Google Scholar
• Livingston PO, Wong GY, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol.12(5), 1036–1044 (1994).
   PubMed Web of Science ®Google Scholar
• Neninger E, Diaz RM, De La Torre A et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a Phase I trial. Cancer Biol. Ther.6(2), 145–150 (2007).
   PubMed Web of Science ®Google Scholar
• Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus bacillus Calmette–Guérin. Clin. Cancer Res.5(6), 1319–1323 (1999).
   PubMed Web of Science ®Google Scholar
• Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with BEC2/bacille Calmette–Guérin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971–08971B; Silva Study). J. Clin. Oncol.23(28), 6854–6864 (2005).
   PubMed Web of Science ®Google Scholar
• Bottomley A, Debruyne C, Felip E et al. Symptom and quality of life results of an international randomised Phase III study of adjuvant vaccination with BEC2/BCG in responding patients with limited disease small-cell lung cancer. Eur. J. Cancer44(15), 2178–2184 (2008).
   PubMed Web of Science ®Google Scholar
• Shariat SF, Chade DC, Karakiewicz PI, Scherr DS, Dalbagni G. Update on intravesical agents for non-muscle-invasive bladder cancer. Immunotherapy2(3), 381–392 (2010).
   PubMedGoogle Scholar
• Vural B, Chen LC, Saip P et al. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer103(12), 2575–2583 (2005).
   PubMed Web of Science ®Google Scholar
• Livingston PO, Hood C, Krug LM et al. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol. Immunother.54(10), 1018–1025 (2005).
   PubMed Web of Science ®Google Scholar
• Abraham DT, Low TH, Messina M et al. Medullary thyroid carcinoma: long-term outcomes of surgical treatment. Ann. Surg. Oncol.18(1), 219–225 (2011).
   PubMed Web of Science ®Google Scholar
• Marinoni I, Pellegata NS. p27kip1: a new multiple endocrine neoplasia gene? Neuroendocrinology93(1), 19–28 (2011).
   PubMedGoogle Scholar
• Traugott A, Moley JF. Medullary thyroid cancer: medical management and follow-up. Curr. Treat. Options Oncol.6(4), 339–346 (2005).
   PubMedGoogle Scholar
• Kebebew E, Greenspan FS, Clark OH, Woeber KA, Grunwell J. Extent of disease and practice patterns for medullary thyroid cancer. J. Am. Coll. Surg.200(6), 890–896 (2005).
   PubMed Web of Science ®Google Scholar
• Bachleitner-Hofmann T, Friedl J, Hassler M et al. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol. Rep.21(6), 1585–1592 (2009).
   PubMedGoogle Scholar
• Papewalis C, Wuttke M, Jacobs B et al. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm. Metab. Res.40(2), 108–116 (2008).
   PubMedGoogle Scholar
• Lien MH, Baldwin BT, Thareja SK, Fenske NA. Merkel cell carcinoma: clinical characteristics, markers, staging and treatment. J. Drugs Dermatol.9(7), 779–784 (2010).
   PubMedGoogle Scholar
• Ramqvist T, Dalianis T. Lessons from immune responses and vaccines against murine polyomavirus infection and polyomavirus-induced tumours potentially useful for studies on human polyomaviruses. Anticancer Res.30(2), 279–284 (2010).
   PubMed Web of Science ®Google Scholar
• Tadmor T, Aviv A, Polliack A. Merkel cell carcinoma, chronic lymphocytic leukemia and other lymphoproliferative disorders: an old bond with possible new viral ties. Ann. Oncol.22(2), 250–256 (2011).
   PubMed Web of Science ®Google Scholar
• Pastrana DV, Tolstov YL, Becker JC, Moore PS, Chang Y, Buck CB. Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog.5(9), e1000578 (2009).
   Google Scholar
• Paulson KG, Carter JJ, Johnson LG et al. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res.70(21), 8388–8397 (2010).
   PubMed Web of Science ®Google Scholar
• Pastrana DV, Gambhira R, Buck CB et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology337(2), 365–372 (2005).
   PubMed Web of Science ®Google Scholar
• Rindi G, Inzani F, Solcia E. Pathology of gastrointestinal disorders. Endocrinol. Metab. Clin. North Am.39(4), 713–727 (2010).
   PubMed Web of Science ®Google Scholar
• Alvarez MC, Macias AA, Saurez MG, Fernandez ML, Lage DA. Bronchial carcinoid tumor treated with interferon and a new vaccine against NeuGcGM3 antigen expressed in malignant carcinoid cells. Cancer Biol. Ther.6(6), 853–855 (2007).
   PubMed Web of Science ®Google Scholar
• Cheah PL, Looi LM. Biology and pathological associations of the human papillomaviruses: a review. Malays. J. Pathol.20(1), 1–10 (1998).
   PubMedGoogle Scholar
• Joseph DA, Miller JW, Wu X et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer113(Suppl. 10), 2892–2900 (2008).
   PubMed Web of Science ®Google Scholar
• Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat. Rev. Clin. Oncol.6(7), 419–428 (2009).
   PubMed Web of Science ®Google Scholar
• Hansel DE, House MG, Ashfaq R, Rahman A, Yeo CJ, Maitra A. MAGE1 is expressed by a subset of pancreatic endocrine neoplasms and associated lymph node and liver metastases. Int. J. Gastrointest. Cancer33(2–3), 141–147 (2003).
   PubMedGoogle Scholar
• Van Baren N, Bonnet MC, Dreno B et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol.23(35), 9008–9021 (2005).
   PubMed Web of Science ®Google Scholar
• Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19–9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat. Dis. Int.8(6), 620–626 (2009).
   PubMed Web of Science ®Google Scholar
• Yuan J, Gnjatic S, Li H et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA105(51), 20410–20415 (2008).
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Brasseur F, Hulsbergen-Van De Kaa CA et al. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int. J. Cancer120(1), 67–74 (2007).
   PubMedGoogle Scholar
• Old LJ. Cancer vaccines: an overview. Cancer Immun.8(Suppl. 1), 1 (2008).
   PubMedGoogle Scholar
• Frick JS, Grunebach F, Autenrieth IB. Immunomodulation by semi-mature dendritic cells: a novel role of Toll-like receptors and interleukin-6. Int. J. Med. Microbiol.300(1), 19–24 (2010).
   PubMed Web of Science ®Google Scholar
• Ilarregui JM, Rabinovich GA. Tolerogenic dendritic cells in the control of autoimmune neuroinflammation: an emerging role of protein-glycan interactions. Neuroimmunomodulation17(3), 157–160 (2010).
   PubMed Web of Science ®Google Scholar
• Weissman D, Ni H, Scales D et al. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J. Immunol.165(8), 4710–4717 (2000).
   PubMedGoogle Scholar
• Simon T, Fonteneau JF, Gregoire M. Dendritic cell preparation for immunotherapeutic interventions. Immunotherapy1(2), 289–302 (2009).
   PubMedGoogle Scholar
• Mueller SN, Jones CM, Stock AT, Suter M, Heath WR, Carbone FR. CD4+ T cells can protect APC from CTL-mediated elimination. J. Immunol.176(12), 7379–7384 (2006).
   PubMedGoogle Scholar
• Ludewig B, Bonilla WV, Dumrese T, Odermatt B, Zinkernagel RM, Hengartner H. Perforin-independent regulation of dendritic cell homeostasis by CD8(+) T cells in vivo: implications for adaptive immunotherapy. Eur. J. Immunol.31(6), 1772–1779 (2001).
   PubMedGoogle Scholar
• Eroukhmanoff L, Oderup C, Ivars F. T-cell tolerance induced by repeated antigen stimulation: selective loss of FOXP3- conventional CD4 T cells and induction of CD4 T-cell anergy. Eur. J. Immunol.39(4), 1078–1087 (2009).
   PubMedGoogle Scholar
• Badovinac VP, Messingham KA, Jabbari A, Haring JS, Harty JT. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med.11(7), 748–756 (2005).
   PubMed Web of Science ®Google Scholar
• Pham NL, Pewe LL, Fleenor CJ et al. Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly. Proc. Natl Acad. Sci. USA107(27), 12198–12203 (2010).
   PubMedGoogle Scholar
• Wong P, Lara-Tejero M,Ploss A, Leiner I, Pamer EG. Rapid development of T cell memory. J. Immunol.172(12), 7239–7245 (2004).
   PubMedGoogle Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J.22(3), 659–661 (2008).
   PubMed Web of Science ®Google Scholar
• Butts CL, Sternberg EM. Neuroendocrine factors alter host defense by modulating immune function. Cell Immunol.252(1–2), 7–15 (2008).
   PubMedGoogle Scholar
• Brubaker PL, Drucker DJ, Asa SL, Swallow C, Redston M, Greenberg GR. Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor. J. Clin. Endocrinol. Metab.87(7), 3078–3083 (2002).
   PubMedGoogle Scholar
• Skinner MM, Nass R, Lopes B, Laws ER, Thorner MO. Growth hormone secretagogue receptor expression in human pituitary tumors. J. Clin. Endocrinol. Metab.83(12), 4314–4320 (1998).
   PubMed Web of Science ®Google Scholar
• Leontiou CA, Franchi G, Korbonits M. Ghrelin in neuroendocrine organs and tumours. Pituitary10(3), 213–225 (2007).
   PubMedGoogle Scholar
• Taylor AW. Neuroimmunomodulation and immune privilege: the role of neuropeptides in ocular immunosuppression. Neuroimmunomodulation10(4), 189–198 (2002).
   PubMedGoogle Scholar
• Garssen J, Buckley TL, Van Loveren H. A role for neuropeptides in UVB-induced systemic immunosuppression. Photochem. Photobiol.68(2), 205–210 (1998).
   PubMed Web of Science ®Google Scholar
• Seiffert K, Granstein RD. Neuropeptides and neuroendocrine hormones in ultraviolet radiation-induced immunosuppression. Methods28(1), 97–103 (2002).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol. Med.13(6), 241–251 (2007).
   PubMedGoogle Scholar
• Taylor AW, Yee DG, Nishida T, Namba K. Neuropeptide regulation of immunity. The immunosuppressive activity of α-melanocyte-stimulating hormone (α-MSH). Ann. NY Acad. Sci.917, 239–247 (2000).
   PubMedGoogle Scholar
• Fabricius D, O’dorisio MS, Blackwell S, Jahrsdorfer B. Human plasmacytoid dendritic cell function: inhibition of IFN-α secretion and modulation of immune phenotype by vasoactive intestinal peptide. J. Immunol.177(9), 5920–5927 (2006).
   PubMedGoogle Scholar
• Moreno AM, Castilla-Guerra L, Martinez-Torres MC, Torres-Olivera F, Fernandez E, Galera-Davidson H. Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas. Neuropeptides33(2), 159–163 (1999).
   PubMedGoogle Scholar
• Wai LE, Garcia JA, Martinez OM, Krams SM. Distinct roles for the NK cell-activating receptors in mediating interactions with dendritic cells and tumor cells. J. Immunol.186(1), 222–229 (2011).
   PubMedGoogle Scholar
• Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Investig. Drugs18(7), 1001–1011 (2009).
   PubMed Web of Science ®Google Scholar
• Leon L, Areses MC, Anido U, Gomez A, Carballo AM. Poxviral-based prostate-specific antigen vaccine in prostate cancer. J. Clin. Oncol.28(24), e416; author reply e417 (2010).
   Google Scholar
• Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, Mccart JA. Intelligent design: combination therapy with oncolytic viruses. Mol. Ther.18(2), 251–263 (2010).
   PubMed Web of Science ®Google Scholar
• Bridle BW, Hanson S, Lichty BD. Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev.21(2–3), 143–148 (2010).
   PubMedGoogle Scholar
• Morton CL, Houghton PJ, Kolb EA et al. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr. Blood Cancer55(2), 295–303 (2010).
   PubMed Web of Science ®Google Scholar